{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:09:10Z","timestamp":1788952150132,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>First-line chemoimmunotherapy has become a major therapeutic strategy for advanced gastric and gastroesophageal junction cancer, yet the magnitude of survival benefit, regional consistency, and toxicity trade-offs remain important considerations. We conducted an systematic review and meta-analysis of randomized controlled trials evaluating PD-1\/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone or placebo plus chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and ClinicalTrials.gov were searched from inception to March 1, 2026. Eligible studies enrolled adults with previously untreated unresectable, recurrent, locally advanced, or metastatic gastric or gastroesophageal junction cancer. Hazard ratios were pooled for overall survival and progression-free survival, and risk ratios were pooled for objective response rate and safety outcomes using random-effects models. Risk of bias was assessed using RoB 2, and certainty of evidence was evaluated using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven randomized controlled trials including 6,517 patients were analyzed. PD-1\/PD-L1 inhibitor plus chemotherapy significantly improved overall survival and progression-free survival. Objective response rate was also increased (RR, 1.24; 95% CI, 1.18\u20131.31), with negligible observed heterogeneity (I\u00b2 = 0.0%). Overall survival effects were similar in global trials (HR, 0.79; 95% CI, 0.75\u20130.85) and Asian-only or China-only trials (HR, 0.81; 95% CI, 0.73\u20130.91; P for subgroup difference = 0.70). The progression-free survival effect was greater in Asian-only or China-only trials (HR, 0.66 vs. 0.78; P for subgroup difference = 0.02), although this analysis was exploratory. Combination therapy increased grade \u22653 treatment-related adverse events (RR, 1.15; 95% CI, 1.08\u20131.23), serious treatment-related adverse events (RR, 1.53; 95% CI, 1.29\u20131.83), and treatment discontinuation (RR, 1.53; 95% CI, 1.37\u20131.72). The pooled estimate for treatment-related death was statistically inconclusive (RR, 1.54; 95% CI, 0.75\u20133.16); the wide confidence interval indicated substantial imprecision and could not exclude clinically important increases or decreases in treatment-related mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>First-line PD-1\/PD-L1 inhibitor + chemotherapy provides a consistent survival and response benefit in advanced gastroesophageal junction or gastric cancer, but with increased clinically relevant toxicity. These findings support chemoimmunotherapy as a preferred first-line strategy for appropriately selected patients, with treatment decisions guided by biomarker status, patient fitness, and toxicity risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1914121","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:47Z","timestamp":1788948767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoli","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Rehabilitation Hospital Affiliated to Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Rehabilitation Hospital Affiliated to Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Cancer Network"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152692","article-title":"Emerging therapeutic targets and future directions in advanced gastric cancer: A comprehensive review","volume":"16","author":"Ratti","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Network","year":"2014","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.003","article-title":"Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649","volume":"37","author":"Janjigian","year":"2026","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32020112","article-title":"Immunotherapy combined with chemotherapy in the first-line treatment of advanced gastric cancer: Systematic review and Bayesian network meta-analysis based on specific PD-L1 CPS","volume":"32","author":"Zhang","year":"2025","journal-title":"Curr Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1564604","article-title":"First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: A meta-analysis of phase 3 trials","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clon.2024.09.007","article-title":"PD-1\/PD-L1 inhibitors in combination with chemo or as monotherapy vs. chemotherapy alone in advanced, unresectable HER2-negative gastric, gastroesophageal junction, and esophageal adenocarcinoma: A meta-analysis","volume":"36","author":"Beshr","year":"2024","journal-title":"Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292465","article-title":"Roadblocks in education amidst global crisis\u2014a study based in India","volume":"18","author":"Dayal","year":"2023","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1651176","article-title":"Long-term outcomes of PD-1 inhibitors plus chemotherapy as first-line treatment for advanced HER2-negative gastric cancer: An updated systematic review and meta-analysis","volume":"16","author":"Tong","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: Results from JAVELIN Gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:47Z","timestamp":1788948767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1914121"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1914121","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1914121"}}